Start | Browse by Day | Author Index | Poster Index

P188 Prevalence of HPV Among Females Prior to HPV Vaccine Introduction in 2 Managed Care Organizations (MCOs)

Wednesday, March 10, 2010
Pre-Function Lobby & Grand Ballroom D2/E (M4) (Omni Hotel)
Eileen Dunne, MD, MPH1, Roger Baxter, MD2, Allison Naleway, PhD3, Nicola Klein, MD, PhD4, Sheila Weinmann, PhD3, Karen Riedlinger, MPH5, Barbara Fetterman, SCT6, Charlie Chao, MPH4, Martin Steinau, PhD7, Mariela Zamarron, PhD7, Julianne Gee, MPH8, Lauri Markowitz, MD1 and Elizabeth Unger, MD, PhD7, 1Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, 2Kaiser Permanente Vaccine Study, Northern California Kaiser Permanente, Oakland, CA, 3Center for Health Research, Kaiser Permanente Northwest, Portland, OR, 4Northern California Kaiser Permanente, Oakland, CA, 5Center for Health Research, Kaiser Permanente, Portland, OR, 6Northern California Kaiser Permanente, Berkeley, CA, 7CDC, Atlanta, GA, 8Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA

Background: One early measure of HPV vaccine impact would be reduction in prevalence of HPV types 6, 11, 16, 18 in cervical specimens from young women.

Objectives: To assess baseline HPV prevalence in cervical specimens collected from females prior to HPV vaccine use in two MCOs.

Methods: Cervical specimens collected during routine cervical cancer screening from 11-29 year old females who had no prior HPV vaccination were consecutively sampled from 2006-2007. In Northern California Kaiser Permanente (NCK), the sample was a swab in Specimen Transport Media (Qiagen, Valencia, CA, USA), and in Northwest Kaiser Permanente (NWK) the sample was a SurePath (TriPath Imaging, Burlington, NC, USA) liquid cytology specimen. Specimens were sent to CDC and evaluated for 37 HPV genotypes using the Roche Linear Array.

Results: A total of 10,209 specimens were evaluated. Overall, 3588 (35%) specimens had any HPV type detected, and this was similar by site (37% in NCK and 33% in NWK). The most common detected type (7.5%) was HPV 16. Prevalence of HPV 6, 11, 16 or 18 was 11.4% and did not vary by site; prevalence was 18% among 11-19 year old females (14% HPV 16 or 18), 12% among 20-24 year old women (10% HPV 16 or 18), and 7% among 25-29 year old women (6% HPV 16 or 18). Among specimens from women with low grade squamous intraepithelial lesions (n=396), 37% had HPV 16 or 18 detected; among specimens from women with high grade squamous intraepithelial lesions (n=31), 64% had HPV 16 or 18 detected.

Conclusions: HPV is commonly detected from women attending routine cervical cancer screening; HPV-16 was most common. HPV vaccine-type prevalence was highest among 11-19 year old females.

Implications for Programs, Policy, and/or Research: Baseline data on HPV prevalence from two MCOs may be useful to evaluate HPV vaccine impact.

See more of: Poster Session 2
See more of: Oral and Poster
<< Previous Abstract | Next Abstract >>